A wound that won't go away
Picture a small blister on the bottom of your foot. For most people, it heals in a week.
For someone with diabetes, that same blister can stay open for months. Sometimes it leads to infection, surgery, or even amputation.
Now imagine a treatment that uses cells from your own body to speed the healing. That's the idea researchers just tested across 26 clinical trials.
Why diabetic foot ulcers are so tough
About 1 in 4 people with diabetes will develop a foot ulcer in their lifetime.
High blood sugar damages nerves and blood vessels. Nerves stop sending pain signals, so small injuries go unnoticed. Blood vessels narrow, so healing slows down.
The result is a wound that your body struggles to close on its own.
Standard care — wound cleaning, special dressings, offloading the foot — helps some people. But many ulcers still linger for six months or more.
That delay is dangerous. Long-open wounds are the top reason for diabetes-related amputations.
The old approach vs. the new one
Traditional care focuses on keeping the wound clean and reducing pressure.
It's like sweeping a floor over and over, hoping the dirt stops coming back. Useful, but often not enough.
Here's what's different about the new approach. Researchers take cells from the patient's own body — usually from bone marrow, fat tissue, or blood — and place them into the wound.
These cells act like tiny repair workers. They help form new blood vessels, grow fresh tissue, and signal the body to heal.
Think of a wound as a construction site missing its workers. Cell therapy is like calling in a specialized crew.
The cells do three main jobs. They build new blood vessels to feed the wound. They release signals that tell skin to grow. And they calm inflammation that was keeping things stuck.
Because the cells come from the patient's own body, there's no rejection and no donor match needed.
It's a very personal form of medicine — your cells, put back to work where your body needs them most.
The study in a nutshell
Researchers pulled together every randomized trial they could find through November 2025.
They ended up with 26 trials and 2,214 patients in total. Each trial compared autologous cell therapy with standard wound care.
They measured three things: how often wounds fully closed, how much the ulcer shrank, and how many days healing took.
Patients who got cell therapy were significantly more likely to have their wounds fully close compared to standard care.
Ulcer size dropped by about 24.6% more in the cell therapy group than in the control group.
In plain language: wounds that would otherwise stay open healed more often, and they got smaller faster.
A moment to pause
These are pooled results from many small trials, not a single large one.
That matters because small studies can sometimes overstate benefits. When many small studies all point in the same direction, though, the signal gets stronger.
Here, the direction is consistent. Cell therapy appears to help.
Where this fits in the bigger picture
Diabetes wound care has stayed mostly the same for decades — clean, dress, protect.
Cell-based treatments represent a shift toward what experts call regenerative medicine. Instead of just protecting a wound, you're actively rebuilding tissue.
This study adds strong support to that shift. It doesn't mean cell therapy replaces standard care. It means it may be a powerful add-on for wounds that won't close.
Cell therapy for diabetic foot ulcers is available in some wound-care centers but is not yet standard everywhere.
If you or a loved one has a foot ulcer that's been open more than a month, ask your doctor or wound specialist about advanced options.
In the meantime, daily foot checks, good blood sugar control, proper footwear, and prompt care for any new wound remain the best prevention.
Catching a wound on day one is still easier than treating it on day one hundred.
Honest limits of the research
Not all 26 trials used the same type of cells or the same protocol. Some used bone marrow cells, others used blood-derived cells.
Sample sizes in many trials were small. Follow-up times were often short. Most studies came from outside the U.S.
Safety reporting was also uneven. We need larger, standardized trials to confirm long-term safety and find the best cell source.
Bigger international trials are underway to compare different cell types head-to-head.
Researchers are also working on "off-the-shelf" versions — ready-to-use cells that don't require harvesting from the patient.
If those succeed, cell therapy could become faster, cheaper, and more widely available.
For now, this review signals that the approach is promising enough to take seriously — and worth asking about if standard care isn't working.
